Citadel Advisors’s Sanofi SNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.3M | Sell |
214,600
-186,600
| -47% | -$8.7M | ﹤0.01% | 3209 |
|
|
2025
Q4 | $19.4M | Buy |
401,200
+106,200
| +36% | +$5.26M | ﹤0.01% | 2385 |
|
|
2025
Q3 | $13.9M | Sell |
295,000
-51,700
| -15% | -$2.5M | ﹤0.01% | 2778 |
|
|
2025
Q2 | $16.7M | Sell |
346,700
-8,900
| -3% | -$455K | ﹤0.01% | 2371 |
|
|
2025
Q1 | $19.7M | Sell |
355,600
-49,500
| -12% | -$2.68M | ﹤0.01% | 2052 |
|
|
2024
Q4 | $19.5M | Sell |
405,100
-4,300
| -1% | -$219K | ﹤0.01% | 2184 |
|
|
2024
Q3 | $23.6M | Buy |
409,400
+241,700
| +144% | +$13M | ﹤0.01% | 1876 |
|
|
2024
Q2 | $8.14M | Sell |
167,700
-145,300
| -46% | -$7.01M | ﹤0.01% | 3052 |
|
|
2024
Q1 | $15.2M | Sell |
313,000
-101,400
| -24% | -$4.95M | ﹤0.01% | 2385 |
|
|
2023
Q4 | $20.6M | Buy |
414,400
+68,000
| +20% | +$3.33M | ﹤0.01% | 1989 |
|
|
2023
Q3 | $18.6M | Sell |
346,400
-71,800
| -17% | -$3.83M | ﹤0.01% | 1945 |
|
|
2023
Q2 | $22.5M | Buy |
418,200
+127,300
| +44% | +$6.85M | ﹤0.01% | 1752 |
|
|
2023
Q1 | $15.8M | Sell |
290,900
-186,300
| -39% | -$9.06M | ﹤0.01% | 2200 |
|
|
2022
Q4 | $23.1M | Buy |
477,200
+74,500
| +19% | +$3.27M | 0.01% | 1815 |
|
|
2022
Q3 | $15.3M | Buy |
402,700
+307,700
| +324% | +$13.7M | ﹤0.01% | 2189 |
|
|
2022
Q2 | $4.75M | Buy |
95,000
+45,000
| +90% | +$2.39M | ﹤0.01% | 3888 |
|
|
2022
Q1 | $2.57M | Sell |
50,000
-81,700
| -62% | -$4.22M | ﹤0.01% | 5536 |
|
|
2021
Q4 | $6.6M | Buy |
131,700
+16,500
| +14% | +$816K | ﹤0.01% | 3819 |
|
|
2021
Q3 | $5.55M | Sell |
115,200
-13,000
| -10% | -$661K | ﹤0.01% | 4110 |
|
|
2021
Q2 | $6.75M | Sell |
128,200
-6,100
| -5% | -$318K | ﹤0.01% | 3818 |
|
|
2021
Q1 | $6.64M | Buy |
134,300
+11,100
| +9% | +$533K | ﹤0.01% | 3692 |
|
|
2020
Q4 | $5.99M | Buy |
123,200
+52,400
| +74% | +$2.58M | ﹤0.01% | 3381 |
|
|
2020
Q3 | $3.55M | Buy |
70,800
+15,400
| +28% | +$793K | ﹤0.01% | 3687 |
|
|
2020
Q2 | $2.83M | Sell |
55,400
-1,400
| -2% | -$68K | ﹤0.01% | 3958 |
|
|
2020
Q1 | $2.48M | Sell |
56,800
-92,500
| -62% | -$4.43M | ﹤0.01% | 3801 |
|
|
2019
Q4 | $7.5M | Buy |
149,300
+124,500
| +502% | +$5.83M | ﹤0.01% | 2555 |
|
|
2019
Q3 | $1.15M | Sell |
24,800
-31,100
| -56% | -$1.34M | ﹤0.01% | 5356 |
|
|
2019
Q2 | $2.42M | Buy |
55,900
+7,000
| +14% | +$298K | ﹤0.01% | 4200 |
|
|
2019
Q1 | $2.17M | Buy |
48,900
+41,800
| +589% | +$1.79M | ﹤0.01% | 4329 |
|
|
2018
Q4 | $308K | Sell |
7,100
-36,400
| -84% | -$1.61M | ﹤0.01% | 7214 |
|
|
2018
Q3 | $1.94M | Buy |
43,500
+10,400
| +31% | +$444K | ﹤0.01% | 4460 |
|
|
2018
Q2 | $1.32M | Sell |
33,100
-30,400
| -48% | -$1.2M | ﹤0.01% | 4747 |
|
|
2018
Q1 | $2.54M | Buy |
63,500
+27,400
| +76% | +$1.14M | ﹤0.01% | 3370 |
|
|
2017
Q4 | $1.55M | Buy |
36,100
+18,100
| +101% | +$835K | ﹤0.01% | 3981 |
|
|
2017
Q3 | $896K | Sell |
18,000
-26,200
| -59% | -$1.27M | ﹤0.01% | 4470 |
|
|
2017
Q2 | $2.12M | Buy |
44,200
+13,200
| +43% | +$631K | ﹤0.01% | 3102 |
|
|
2017
Q1 | $1.4M | Sell |
31,000
-18,400
| -37% | -$781K | ﹤0.01% | 3517 |
|
|
2016
Q4 | $2M | Sell |
49,400
-200
| -0.4% | -$7.88K | ﹤0.01% | 2949 |
|
|
2016
Q3 | $1.89M | Sell |
49,600
-5,300
| -10% | -$213K | ﹤0.01% | 3027 |
|
|
2016
Q2 | $2.3M | Buy |
+54,900
| New | +$2.25M | ﹤0.01% | 2599 |
|
Other funds holding SNY
MIP
Citadel Advisors's SNY Position: Q1 2026 in Review
Citadel Advisors increased its Sanofi (SNY) stake by 19% in Q1 2026, buying an estimated $11M and bringing the position to 1,487,970 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #1058.
Citadel Advisors first reported a position in SNY in Q2 2013 and has held it in 38 quarters since. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.
- Citadel Advisors held 1,487,970 shares of Sanofi worth $71.7M as of Q1 2026.
- Citadel Advisors bought 235,434 Sanofi shares in Q1 2026, an estimated $11M.
- Sanofi made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1058 holding.
- Citadel Advisors first reported a position in Sanofi in Q2 2013 and has held it in 38 quarters since.
- 737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.